Lesion-directed therapies and monitoring tumor evolution using liquid biopsies

Cold Spring Harbor Perspectives in Medicine

Volumn 7, Issue 2, 2017, Pages

  Russo, Mariangela ^a,b   Bardelli, Alberto ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOPSY TECHNIQUE; CANCER RESISTANCE; CARCINOGENESIS; CLONAL EVOLUTION; DRUG RECHALLENGE; EVIDENCE BASED PRACTICE; GENETIC HETEROGENEITY; HUMAN; LIQUID BIOPSY; MOLECULARLY TARGETED THERAPY; ONCOGENESIS AND MALIGNANT TRANSFORMATION; PERSONALIZED MEDICINE; PHARMACEUTICAL CARE; THERAPY RESISTANCE; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR HETEROGENEITY; DRUG RESISTANCE; GENETICS; MUTATION; NEOPLASM; PATHOLOGY; PROCEDURES;

ANTINEOPLASTIC AGENT; DNA;

ANTINEOPLASTIC AGENTS; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; HUMANS; LIQUID BIOPSY; MUTATION; NEOPLASMS;

EID: 85011591335     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a029587     Document Type: Article

References (79)

1. Alix-Panabières C, Pantel K. 2013. Circulating tumor cells: Liquid biopsy of cancer. Clin Chem 59: 110–118.
2. Alix-Panabières C, Pantel K. 2016. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov 6: 479–491.
3. Alix-Panabières C, Bartkowiak K, Pantel K. 2016. Functional studies on circulating and disseminated tumor cells in carcinoma patients. Mol Oncol 10: 443–449.
4. Arena S, Bellosillo B, Siravegna G, Martinez A, Canadas I, Lazzari L, Ferruz N, Russo M, Misale S, Gonzalez I, et al. 2015. Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin Cancer Res 21: 2157–2166.
5. Ashworth TR. 1869. Acase of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J 14: 146–149.
6. Balduin M, Sierra S, Da¨umer MP, Rockstroh JK, Oette M, Fätkenheuer G, Kupfer B, Beerenwinkel N, Hoffmann D, Selbig J, et al. 2005. Evolution of HIV resistance during treatment interruption in experienced patients and after restarting a new therapy. J Clin Virol 34: 277–287.
7. Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, et al. 2013. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 3: 658–673.
8. Beaver JA, Jelovac D, Balukrishna S, Cochran RL, Croessmann S, Zabransky DJ, Wong HY, Valda Toro P, Cidado J, Blair BG, et al. 2014. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res 20: 2643–2650.
9. Bedard PL, Hansen AR, Ratain MJ, Siu LL. 2013. Tumour heterogeneity in the clinic. Nature 501: 355–364.
10. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al. 2014. Detection of circulating tumor DNA in early- and latestage human malignancies. Sci Transl Med 6: 224ra224.
11. Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, Van Allen EM, Lawrence MS, Horowitz PM, Cibulskis K, et al. 2015. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov 5: 1164–1177.
12. Brawley OW, Thompson IM, Grönberg H. 2016. Evolving recommendations on prostate cancer screening. Am Soc Clin Oncol Educ Book 35: e80–e87.
13. Burrell RA, McGranahan N, Bartek J, Swanton C. 2013. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501: 338–345.
14. Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, et al. 2016. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun 7: 11815.
15. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, Yatabe Y, Takeuchi K, Hamada T, Haruta H, et al. 2010. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363: 1734–1739.
16. Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M, Stuart DD. 2013. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494: 251–255.
17. Diaz LA, Bardelli A. 2014. Liquid biopsies: Genotyping circulating tumor DNA. J Clin Oncol 32: 579–586.
18. Diaz LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, et al. 2012. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486: 537–540.
19. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, et al. 2008. Circulating mutant DNA to assess tumor dynamics. Nat Med 14: 985–990.
20. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan MD, et al. 2012. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing.Nature 481: 506–510.
21. Fisher R, Pusztai L, Swanton C. 2013. Cancer heterogeneity: Implications for targeted therapeutics. Br J Cancer 108: 479–485.
22. Gatenby RA, Silva AS, Gillies RJ, Frieden BR. 2009. Adaptive therapy. Cancer Res 69: 4894–4903.
23. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, et al. 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366: 883–892.
24. Greaves M, Maley CC. 2012. Clonal evolution in cancer. Nature 481: 306–313.
25. Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann EM, Lax S, Waldispuehl-Geigl J, Mauermann O, Lackner C, et al. 2013. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and nextgeneration sequencing. Cancer Res 73: 2965–2975.
26. Imamura F, Uchida J, Kukita Y, Kumagai T, Nishino K, Inoue T, Kimura M, Oba S, Kato K. 2016. Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer. Lung Cancer 94: 68–73.
27. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R. 2001. DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61: 1659–1665.
28. Jen J, Wu L, Sidransky D. 2000. An overview on the isolation and analysis of circulating tumor DNA in plasma and serum. Ann NY Acad Sci 906: 8–12.
29. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, Fouse SD, Yamamoto S, Ueda H, Tatsuno K, et al. 2014.Mutational analysis reveals the origin and therapydriven evolution of recurrent glioma. Science 343: 189–193.
30. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, Benes C, et al. 2012. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 4: 120ra117.
31. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, Van Wier S, Blackburn PR, Baker AS, Dispenzieri A, et al. 2012. Clonal competition with alternating dominance in multiple myeloma. Blood 120: 1067–1076.
32. Kobayashi S, Boggon TJ, Dayaram T, Ja¨nne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. 2005. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786–792.
33. Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M, Tada H, Kuwano H, Mitsudomi T. 2006. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12: 5764–5769.
34. Kurata T, Tamura K, Kaneda H, Nogami T, Uejima H, Asai Go G, Nakagawa K, Fukuoka M. 2004. Effect of re-treatment with gefitinib (“Iressa,” ZD1839) after acquisition of resistance. Ann Oncol 15: 173–174.
35. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, Sougnez C, Stewart C, Sivachenko A, Wang L, et al. 2013. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152: 714–726.
36. Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, Kluth S, Bozic I, Lawrence M, Böttcher S, et al. 2015.Mutations driving CLL and their evolution in progression and relapse. Nature 526: 525–530.
37. Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, O’Shaughnessy J, Kinzler KW, Parmigiani G, Vogelstein B, et al. 2012. Detection of chromosomal alterations in the circulation of cancer patients with wholegenome sequencing. Sci Transl Med 4: 162ra154.
38. Liegl B, Kepten I, Le C, Zhu M, Demetri GD, Heinrich MC, Fletcher CD, Corless CL, Fletcher JA. 2008. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 216: 64–74.
39. Maindrault-Goebel F, Tournigand C, André T, Carola E, Mabro M, Artru P, Louvet C, de Gramont A. 2004. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann Oncol 15: 1210–1214.
40. Mandel P, Metais P. 1948. Les acides nucléiques du plasma sanguin chez l’homme [Nucleic acids in the blood of humans]. C R Seances Soc Biol Fil 142: 241–243.
41. Martinez-Picado J, Martínez MA. 2008. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: A view from the clinic and ex vivo. Virus Res 134: 104–123.
42. Marusyk A, Almendro V, Polyak K. 2012. Intra-tumour heterogeneity: A looking glass for cancer?Nat Rev Cancer 12: 323–334.
43. Meacham CE, Morrison SJ. 2013. Tumour heterogeneity and cancer cell plasticity. Nature 501: 328–337.
44. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, et al. 2012. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486: 532–536.
45. Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, Russo M, Buscarino M, Lazzari L, Sartore-Bianchi A, et al. 2014. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med 6: 224ra226.
46. Misale S, Bozic I, Tong J, Peraza-Penton A, Lallo A, Baldi F, Lin KH, Truini M, Trusolino L, Bertotti A, et al. 2015. Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. Nat Commun 6: 8305.
47. Mohan S, Heitzer E, Ulz P, Lafer I, Lax S, Auer M, Pichler M, Gerger A, Eisner F, Hoefler G, et al. 2014. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet 10: e1004271.
48. Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, et al. 2008. Elevated CRAFas a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 68: 4853–4861.
49. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS, et al. 2013.Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497: 108–112.
50. Murtaza M, Dawson SJ, Pogrebniak K, Rueda OM, Provenzano E, Grant J, Chin SF, Tsui DW, Marass F, Gale D, et al. 2015.Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat Commun 6: 8760.
51. Murugaesu N, Wilson GA, Birkbak NJ, Watkins TB, Mc-Granahan N, Kumar S, Abbassi-Ghadi N, Salm M, Mitter R, Horswell S, et al. 2015. Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. Cancer Discov 5: 821–831.
52. Nowell PC. 1976. The clonal evolution of tumor cell populations. Science 194: 23–28.
53. Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O’Connell A, Messineo MM, Luke JJ, Butaney M, Kirschmeier P, Jackman DM, et al. 2014. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 20: 1698–1705.
54. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. 2005. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73.
55. Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, Telli ML, Advani RH, Carlson RW, Mollick JA, et al. 2012. Single cell profiling of circulating tumor cells: Transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS ONE 7: e33788.
56. Russo M, Misale S, Wei G, Siravegna G, Crisafulli G, Lazzari L, Corti G, Rospo G, Novara L, Mussolin B, et al. 2016a. Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer. Cancer Discov 6: 36–44.
57. Russo M, Siravegna G, Blaszkowsky LS, Corti G, Crisafulli G, Ahronian LG, Mussolin B, Kwak EL, Buscarino M, Lazzari L, et al. 2016b. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discov 6: 147–153.
58. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL. 2002. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117–125.
59. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, et al. 2012. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486: 395–399.
60. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, et al. 2014. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 4: 80–93.
61. Siravegna G, Bardelli A. 2014. Minimal residual disease in breast cancer: In blood veritas. Clin Cancer Res 20: 2505–2507.
62. Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, et al. 2015. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 21: 827.
63. Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL. 1994. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev 3: 67–71.
64. Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC, Curtis C, Watts C, Tavaré S. 2013. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci 110: 4009–4014.
65. Sprouffske K, Merlo LM, Gerrish PJ, Maley CC, Sniegowski PD. 2012. Cancer in light of experimental evolution. Curr Biol 22: R762–R771.
66. Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z, et al. 2010. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med 2: 25ra23.
67. Swanton C. 2014. Cancer evolution: The final frontier of precision medicine? Ann Oncol 25: 549–551.
68. Tie J, Kinde I, Wang Y, Wong HL, Roebert J, Christie M, Tacey M, Wong R, Singh M, Karapetis CS, et al. 2015. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol 26: 1715–1722.
69. Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, et al. 2006. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—A GERCOR study. J Clin Oncol 24: 394–400.
70. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, et al. 2010. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17: 77–88.
71. Vasioukhin V, Anker P, Maurice P, Lyautey J, Lederrey C, Stroun M. 1994. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol 86: 774–779.
72. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. 2013. Cancer genome landscapes. Science 339: 1546–1558.
73. Weigelt B, Reis-Filho JS. 2009. Histological and molecular types of breast cancer: Is there a unifying taxonomy? Nat Rev Clin Oncol 6: 718–730.
74. Welch HG, Albertsen PC. 2009. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Inst 101: 1325–1329.
75. Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C. 2012. Intratumor heterogeneity: Seeing the wood for the trees. Sci Transl Med 4: 127ps110.
76. Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, Van Loo P, Aas T, Alexandrov LB, Larsimont D, Davies H, et al. 2015. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med 21: 751–759.
77. Yoshimoto A, Inuzuka K, Kita T, Kawashima A, Kasahara K. 2007. Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib. Am J Med Sci 333: 221–225.
78. Yu M, Stott S, Toner M, Maheswaran S, Haber DA. 2011. Circulating tumor cells: Approaches to isolation and characterization. J Cell Biol 192: 373–382.
79. Zama IN, Hutson TE, Elson P, Cleary JM, Choueiri TK, Heng DY, Ramaiya N, Michaelson MD, Garcia JA, Knox JJ, et al. 2010. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 116: 5400–5406.